EVRYS BIO LLC
DOYLESTOWN, PA · Founded 2012 · CIK 0001597945 · Biotech · Private
Broad-spectrum antiviral therapies targeting multiple viral families while preventing resistance
evrysbio.com →- Grants
- $14M
- 16 awards
- Sector median: 1
- Raised
- $548K
- 3 Form D · Jan 2022
- 57 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 10
- 3 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $200,000 | |
| Federal grant | Department of Health and Human Services · Phase I · An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML) | $224,999 | |
| Private capital raised | Form D · SEC | $347,500 | |
| Federal grant | Department of Health and Human Services · Phase II · Sirtuin Agonists As Pan Influenza Antivirals | $304,858 | |
| Federal grant | Department of Health and Human Services · Phase II · Sirtuin Agonists As Pan Influenza Antivirals | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Sirtuin Agonists As Pan Influenza Antivirals | $2,000,000 | |
| Federal grant | Department of Defense · Phase I · Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus | $149,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Sirtuin Agonists As Pan Influenza Antivirals | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $999,997 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $901,086 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $999,998 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $983,882 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $961,797 | |
| Federal grant | Department of Health and Human Services · Phase II · A single antiviral to treat multiple opportunistic infections | $978,771 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure | $961,797 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2593 | Dawah Pharmaceuticals, Inc. | — | $580K |
| 2594 | Collidion Inc. | — | $575K |
| 2595 | Animantis LLC | — | $550K |
| 2596 | EVRYS BIO LLC | — | $548K |
| 2597 | Nascent Biotech Inc. | — | $543K |
| 2598 | Mitochondria in Motion, Inc. | — | — |
| 2599 | SKYRAN BIOLOGICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Lillian ChiangDirector · Executive Officer
- Steve HoltzmanDirector
- Steven HoltzmanDirector
- Brian PuschDirector
- Thomas ShenkDirector · Executive Officer
- Richard WhitleyDirector
Patents
- Broad Spectrum Antiviral Compositions and Methodsapplication
- Broad Spectrum Antiviral Compositions and Methodsgranted
- Anti-Tumor Compositions and Methodsapplication
- Broad Spectrum Antiviral Compositions and Methodsgranted
- Anti-hcmv Compositions And Methodsgranted
- Anti-hcmv Compositions And Methodsapplication
- Anti-hcmv Compositions And Methodsapplication
- Broad Spectrum Antiviral Compositions And Methodsapplication
- Anti-tumor Compositions And Methodsapplication
- Anti-tumor Compositions and Methodsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.